Who
David Hung
Director
Company insider
Files Form 4 as: Director, NovoCure; President and CEO, Nuvation Bio; Director, Arya Sciences Acquisition; Director, Establishment Labs Holdings; Principal Executive Officer, Axovant Sciences; President and CEO, Medivation; Director, Opexa Therapeutics.
In numbers
- Trades disclosed
- 167
- Buys
- 4
- Sells
- 44
- Bought
- $11.7M
- Sold
- $73.7M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 5 Apr 2005
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 27 Feb 2026filed 3 Mar 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,995,012 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,995,012 at $0.00 | filing |
| 16 Jun 2025filed 18 Jun 2025 | NUVB Nuvation BioBiotechnology | SEC FORM 4 Bought | $895K500,000 at $1.79 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,697 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,215 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $17K999 at $17.30 | filing |
| 7 Apr 2025filed 8 Apr 2025 | NUVB Nuvation BioBiotechnology | SEC FORM 4 Bought | $489K300,000 at $1.63 | filing |
| 4 Apr 2025filed 8 Apr 2025 | NUVB Nuvation BioBiotechnology | SEC FORM 4 Bought | $332K200,000 at $1.66 | filing |
| 28 Feb 2025filed 4 Mar 2025 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —6,229 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —4,053 at $0.00 | filing |
| 29 Feb 2024filed 4 Mar 2024 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —12,554 at $0.00 | filing |
| 28 Feb 2023filed 2 Mar 2023 | NUVB Nuvation Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500,000 at $0.00 | filing |
News
Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)NVCR · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name David Hung; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.